Last updated on September 2016

Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis


Brief description of study

The purpose of this study is to evaluate the effectiveness of paclitaxel-coated balloon catheter to prevent restenosis after PTA (percutaneous transluminal angioplasty) of hemodialysis access (HA) in comparison with the uncoated PTA balloon catheter.

Detailed Study Description

In Canada, there are over 20,000 patients with chronic end-stage renal disease (ESRD)on long-term hemodialysis and the number is increasing rapidly.The creation of hemodialysis access (HA) (also called "lifeline" for dialysis patients) has become the most common type of vascular surgery. These HA are frequently complicated by dysfunction after their creation mainly due to neointimal hyperplastic stenosis (> 60% at one year). PTA is an established cornerstone method of treating stenotic lesions because of its minimally invasive percutaneous nature and widespread availability.Although PTA has a high initial success rate,narrowing will often recur in 2-3 months hence requiring further interventions. There are currently no durable therapies for the prevention or treatment of HA dysfunction restenosis after PTA. Recently drug eluting balloon (DEB) with paclitaxel have repeatedly demonstrated their effectiveness to prevent restenosis due to intimal proliferation in the coronary and peripheral arterial systems. The investigators believe that the DEB with paclitaxel will significantly decrease the HA restenosis rate at the treated site and therefore will improve the management of HA failures.

Clinical Study Identifier: NCT01928498

Contact Investigators or Research Sites near you

Start Over

Serge Cournoyer, MD

H pital Charles-Lemoyne
Longueuil, QC Canada
  Connect »

Éric Therasse, MD

Centre Hospitalier de l'universit de Montr al-CHUM
Montreal, QC Canada
2.69miles
  Connect »

Jennifer Satterthwaite, M.Sc.

H pital Maisonneuve-Rosemont
Montreal, QC Canada
3.48miles
  Connect »